Literature DB >> 25808506

Western immunoblotting as a new tool for investigating direct antiglobulin test-negative autoimmune hemolytic anemias.

Evgenia M Bloch1,2, Darinka Sakac2, Haley A Branch3, Christine Cserti-Gazdewich1,2,3,4, Jacob Pendergrast1,3,4, Katerina Pavenski1,5, Donald R Branch1,2,3,4.   

Abstract

BACKGROUND: Direct antiglobulin test-negative (DAT(-)) autoimmune hemolytic anemia, characterized by hemolysis without detectable immunoglobulin or complement on patient red blood cells (RBCs), poses a diagnostic challenge. To select therapy, classification of the hemolysis as immune- or non-immune-mediated is important. We developed a method using Western immunoblot (WB) to classify DAT(-) patients by measuring and comparing levels of RBC immunoglobulin (Ig)G to normal donors. STUDY DESIGN AND METHODS: RBC samples from 42 normal donors were made into ghosts and analyzed by WB and densitometry to establish a normal mean relative quantity of IgG (RQIgG) on the RBCs. RQIgG on eight DAT(-) and eluate-negative patients with hemolytic anemia was determined and compared to RQIgG on normal RBCs.
RESULTS: RQIgG of 42 normal donors indicated a calculated mean ± SD of 0.0016 ± 0.0015 and we used a cutoff of 0.0047, the mean + 2SD. This was compared with a receiver operating curve cutoff of 0.0041 with 100% sensitivity and 93% specificity. Of the eight patients tested, three were classified as non-immune-mediated (one had pyruvate kinase deficiency) and five as immune-mediated. Two of the patients in the latter group underwent splenectomy, followed by remission.
CONCLUSION: WB analysis is more sensitive than conventional test tube DAT or elution analysis. Our assay confirms: 1) previous studies showing normal RBCs are sensitized with IgG, perhaps due to natural autoantibody to senescence; 2) that some normal RBCs have increased levels of IgG without signs of disease; and 3) that WB distinguishes between non-immune- and immune-mediated hemolytic anemia in DAT(-) patients and may be useful for clinical diagnosis.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25808506     DOI: 10.1111/trf.13082

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  A Novel Point-of-Care Biomarker Recognition Method: Validation by Detecting Marker for Diabetic Nephropathy.

Authors:  Sahana Pentyala; John Muller; Thomas Tumillo; Avijit Roy; Pooja Mysore; Srinivas Pentyala
Journal:  Diagnostics (Basel)       Date:  2015-04-23

Review 2.  Clinically and/or Serologically Misleading Findings Surrounding Immune Haemolytic Anaemias.

Authors:  Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2015-08-10       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.